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Background/aim: There have been conflicting results in the literature regarding the relationship between functional system involvement,
the expanded disability status scale (EDSS), and the presence of restless legs syndrome (RLS) in patients with multiple sclerosis (MS).
Materials and methods: Ninety-one patients with MS and 40 patients in a control group (headache, essential tremor, and benign
positional paroxysmal vertigo) were studied. The patients underwent a complete neurological examination and Kurtzke functional
system scores were calculated. In order to assess the temporal relation between the onset of RLS and MS, a semistructured interview
guided by a questionnaire about RLS was applied to all of the patients.
Results: Sixteen (17.6%) of the patients with MS and 1 (2.5%) patient in the control group had RLS. The prevalence of RLS was higher in
patients with MS, compared to the control group (P = 0.018). Among the patients with MS, none of them suffered from RLS before the
onset of MS, whereas sixteen patients (16%) suffered RLS after the onset of MS. There was no significant relationship between functional
system involvement and the presence of RLS.
Conclusion: The prevalence of RLS was higher in MS patients than it was in the control group. No association was found between RLS
and functional system involvement in MS patients.
Key words: Multiple sclerosis, restless legs syndrome, EDSS

1. Introduction
Restless legs syndrome (RLS) is a sleep disorder characterized
by an urge to move the legs associated with uncomfortable
paresthesias. Usually, the symptoms manifest in the evening
or at night, when the patients take rest, and are relieved by
walking or moving the legs (1). Diagnosis of RLS needs to
involve the following clinical features: (a) uncomfortable
and unpleasant sensations in the legs, (b) worsening of
the symptoms during rest, (c) relief of the symptoms by
movement, (d) exacerbation of the sensitive disturbance
in the evening or at night (1). The majority of RLS cases
are commonly classified as idiopathic and include sporadic
and inherited forms. Secondary form of RLS has been
associated with iron deficiency, renal failure, pregnancy,
antidopaminergic therapy, rheumatoid arthritis, or several
neurological disorders, including peripheral neuropathy,
spinocerebellar ataxia, essential tremor, Parkinson disease,
and myelopathies (2–4). The etiopathogenesis of RLS is
unknown, yet there is increasing evidence of dopaminergic
neurotransmission dysfunction (5–9).
RLS prevalence has been reported to be 1.2%–15%
and 12.12%–65.1% in the general population and in MS
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patients, respectively (10–30). RLS symptoms appear
usually after the onset of MS (18–20,23,26,27). There is
no relationship between MS subtypes and the presence
of RLS (18,20,22–25,31). There are only three studies that
investigated the relationship between functional system
involvement and the presence of RLS in MS patients
(19,23,25). Two of them showed that there was a significant
relationship between some functional system involvement
and RLS (19,25). In contrast, Deriu et al. did not find any
relationship between the presence of RLS and functional
system involvement (23). Some studies suggested that the
expanded disability status scale (EDSS) was not related to
RLS in MS patients (22,23). However, other studies showed
that EDSS score was higher in MS patients with RLS than
in those without RLS (18–20,30).
Lesion localization in brain MRI did not show any
relationship with the presence of RLS in MS patients
in most studies (18–20,22,23). There is only one study
showing that MS patients with RLS (MS/RLS+) and
patients without RLS (MS/RLS–) had similar cervical cord
lesion load, but with less fractional anisotropy in cervical
and brain MRI in the latter.
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Because there are conflicting results in the literature,
we decided to investigate whether there was a difference
among patients with MS and the control group (patients
with headache, essential tremor, and benign positional
paroxysmal vertigo), in regard to the prevalence of RLS.
We also compared the relationship between functional
system involvement, EDSS score, and the presence of RLS
in MS patients. Moreover, we investigated brain lesion
localization in MS/RLS+ and MS/RLS– patients.
2. Materials and methods
A prospective cohort study was conducted at one of
Ankara’s major teaching hospitals (Ankara University,
İbni Sina Hospital, Turkey) from October 2006 to March
2009. Approval was obtained from the research ethics
committee in advance. Written informed consent was
acquired from all the patients. Participants were chosen
solely from among those who visited the outpatient clinic.
Ninety-one consecutive patients with a definitive MS
diagnosis (67 female, 24 male) and 40 control patients
(27 female, 13 male) were recruited. The control group
consisted of patients with headache, essential tremor,
or benign positional paroxysmal vertigo. The following
criteria were evaluated for both study groups: age, sex, MS
course, disease duration of MS, other underlying acute or
chronic disease, and name and duration of the treatment
intake related to MS. Exclusion criteria for the study
were anemia, chronic renal failure, hypothyroidism, and
diabetes mellitus.
A semistructured interview guided by a RLS
questionnaire was applied to all of the patients. The
temporal relation between the onset of RLS and MS
(before or after the onset of MS, or during relapses)
was questioned if RLS was present in the MS group.
Patients were interviewed by two neurology specialists
who were trained for the questionnaire. Patients were
diagnosed with RLS if they fulfilled all four criteria.
All of the patients underwent a complete neurological
examination. Functional systems were assessed according
to Kurtzke functional system scores and EDSS scores (32).
Localization of the MS lesions (frontal, parietal, temporal,
occipital, mesencephalon, pons, cerebellum, thalamus,
caudate nucleus, putamen, globus pallidus, and internal
capsule) on MRI was noted. Moreover, the mini-mental
state examination (MMSE) was applied to all patients.
2.1. Statistical analysis
Student’s t test was used to compare independent
quantitative data. A chi-squared test was used to compare
independent categorical variables. A P value <0.05 was
considered statistically significant. All statistical analyses
were performed using SPSS version 11.5 for Windows.

3. Results
The MS group and the control group had a mean age of
37.6 and 35.4 years, respectively; the difference was not
significant (P = 0.23). There were 24 males (26.4%) and 67
females (73.6%) in the MS group and 13 (32.5%) males and
27 (67.5%) females in the control group (P = 0.47). Average
disease duration was 8.0 (1–32) years in the MS group.
Among the patients with MS, 71 (78%) had relapsingremitting MS (RRMS), 8 (8.8%) had secondary progressive
MS (SPMS), 3 (3.3%) had progressive relapsing MS (PRMS),
and 9 (9.9%) had primary progressive MS (PPMS). The
median number of attacks was 3 (1–20) and the median
EDSS score was 3 (0–9) in the MS group (Table 1).
Sixteen (17.6%) MS patients had RLS and 75 (82.4%)
did not. One (2.5%) of the control patients had RLS; the
difference was significant (P = 0.018) (Figure). There
were no significant differences regarding age, sex, disease
duration, the presence of depression, antidepressive or
immunomodulatory drugs use, or the presence of median
EDSS score between MS/RLS+ and MS/RLS– patients (P >
0.05 for each) (Table 1).
None of the 16 MS/RLS+ patients had RLS before the
onset of MS and all of them had RLS after the onset of
MS (17.6%). Ten of the 16 MS/RLS+ patients described
an increase in RLS symptoms during MS attacks (11%).
There was no relationship between functional system
involvement and the presence of RLS (P > 0.05 for each)
(Table 2).
RLS was found in 15/56 (21.1%) of the patients with
RRMS and in 1/2 (33.3%) of those with PRMS (Table
1). There was no RLS+ patient in the SPMS and PPMS
groups. Although there was a tendency towards a higher
prevalence of RLS in RRMS than in progressive MS, the
difference was not statistically significant (P = 0.18).
Ten (11%) MS/RLS+ patients described that their RLS
related symptoms appeared or were aggravated during
MS attacks, and eight of them underwent brain MRI
during the same period. Twenty-one MS/RLS– patients
underwent brain MRI during their relapse period. There
was no difference in regard to lesion localization among
MS/RLS+ and MS/RLS– patients on brain MRI that was
acquired during the relapse period (P > 0.05) (Table 3).
Only five patients underwent spinal MRI in the MS/RLS–
group during their relapse period. Cervical plaques were
observed in three MS/RLS– patients.
4. Discussion
Our study showed that the lifetime prevalence of RLS
(17.6%) was significantly higher in MS patients than it was
in the control group (2.5%). Auger et al. performed the
earliest investigation on this topic, and reported that RLS
prevalence was 37.5% in 200 patients with MS and 16% in a
control group with 100 participants (17). A RLS prevalence

1269

SORGUN et al. / Turk J Med Sci
Table 1. Demographic features and presence of other chronic conditions in MS/RLS+ and MS/RLS– patients and the control group.
MS/RLS+ (16)

MS/RLS– (75)

Total MS (91)

P

Control group (40)

Age (mean)

38.2

37.5

37.6

0.23

35.4

Sex (F/M)

14 / 2

53/22

67/24

0.47

27/17

Disease duration, year, Median (Min–Max)

8.0 (1–32)

8.0 (1–18)

8.0 (1–32)

0.14

RRMS

15 (93.8%)

56 (74.7%)

71 (78.0%)

0.19

SPMS

-

8 (10.6%)

8 (8.8%)

PPMS

-

9 (12.0%)

9 (9.9%)

PRMS

1 (6.2%)

2 (2.7%)

3 (3.3%)

Attack number, Median (Min–Max)

4 (1–7)

3 (1–20)

3 (1–20)

0.26

EDSS, Median (Min–Max)

3 (0–4.5)

3 (0–9)

3 (0–9)

0.80

MMSE (mean)

28

27

28

0.45

Immunomodulatory drugs usage (name, dose)

0.84

-interferon beta - 1a 44 µg

1

9

-interferon beta - 1a 6 MIU

3

10

-interferon beta - 1b 22 µg

2

8

-glatiramer acetate 20 mg

2

5

EDSS: expanded disability status scale, RRMS: relapsing-remitting MS, SPMS: secondary progressive MS, PRMS: progressive relapsing
MS, PPMS: primary progressive MS, MMSE: mini-mental status examination
80
70

RLS+

60

RLS–

50
40
30
20
10
0

MS

Control

Figure. Prevalence of RLS was higher in MS patients than it was
in the control group (P = 0.018).

of 32.5% was reported in 156 MS patients by Manconi et
al. (18). In a multicenter case control study by Manconi et
al., RLS prevalence was 19% in 864 MS patients and 4.2%
in 649 healthy controls (19). Moreira et al. showed that the
prevalence of RLS was 27% in 44 MS patients (20). A recent
study reported that RLS frequency was 13.3% in 135 MS
patients and 9.3% in a control group. In that study GómezChoco et al. showed that the prevalence of RLS was similar
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to that in the general population (22). Deriu et al. reported
that RLS prevalence was 14.6% in 202 MS patients and
2.8% in 212 healthy controls (23). Moderate to severe and
very severe RLS symptoms were reported in 57.5% of 80
MS patients and 15% of 180 controls by Farogaso et al.
(24). Aydar et al. showed that RLS frequency was 27.6%
in 98 MS patients and 10.1% in 128 healthy volunteers
(25). Liu et al. demonstrated that the prevalence of RLS
and severe RLS was 15.5% and 9.9%, respectively, among
woman with MS and it was 6.4% and 2.6%, respectively,
among women without MS (26). Miri et al. reported that
RLS prevalence was 27.8% in 205 MS patients (27). In a
recent study by Shaygannejad et al., the prevalence of RLS
was 65.1% in MS patients and 12.7% in a control group
(30). In agreement with most of the previous reports, we
found that the prevalence of RLS was higher in MS patients
than in the control group (17,19,23–27,29,30).
Age and sex in MS/RLS+ patients have been reported
to be similar to those in MS/RLS– patients in most studies
(17,20,22–27). There are other studies showing that the
duration of MS did not show any difference between
groups, MS/RLS+ patients were older and had higher EDSS
scores than MS/RLS– patients (18–20,30). On the other
hand, other studies showed that EDSS score in MS/RLS+
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Table 2. Functional system involvement in MS/RLS+ and MS/RLS– patients.
MS/RLS+

MS/RLS–

(+)

3
10.3%

26
89.7%

(–)

3
30%

7
70%

(+)

3
14.3%

18
85.7%

(–)

3
16.7%

15
83.3%

(+)

1
4.8%

20
95.2%

(–)

5
27.8%

13
72.2%

(+)

6
19.4%

25
80.6%

(–)

0
0%

8
100%

(+)

3
12%

11
88%

(–)

3
21.4%

22
78.6%

(+)

1
16.7%

5
83.3%

(–)

5
15.2%

28
84.8%

Pyramidal

Cerebellar

Brain stem

Sensorial

Bowel/bladder

Visual

P

0.16

0.84

0.07

0.31

0.64

0.66

Table 3. Brain MRI in MS/RLS+ and MS/RLS– patients during the relapse period.
MS/RLS+

MS/RLS–

P

7
6

19

0.63

16

0.64

17

0.54

frontal

(+)

parietal

(+)

temporal

(+)

occipital

(+)

6

18

0.42

mesencephalon

(+)

5

0.64

pons

(+)

2
1

3

0.69

bulbus

(+)

2

0.63

cerebellum

(+)

11

0.61

thalamus

(+)

1

0.72

caudate nucleus

(+)

2

0.51

putamen and globus pallidus

(+)

2

0.51

internal capsule

(+)

1

0.72

6

1
4
0
0
0
0
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patients was similar to that in MS/RLS– patients (22,23).
Age, sex, disease duration, and EDSS scores in MS/RLS+
patients were similar to those in MS/RLS– patients in our
study, compatible with some of the previous studies. We
also found that anemia and immunomodulatory drug use
did not differ between the MS/RLS+ and MS/RLS– groups.
Therefore we concluded that immunomodulatory drug
use had no effect on the prevalence of MS.
Moreire et al. reported that 11 of 35 RRMS patients and
1 of 4 PPMS patients had RLS (20). Manconi et al. showed
that RLS prevalence was higher in PPMS than it was in
other types of MS (19). Farogaso et al. reported that 5
patients presented with SPMS, while 75 patients presented
with RRMS (24). There was a significant relationship
between the type of MS and RLS, according to Aydar et al.
(25). Miri et al. showed that 91.2% of patients (52 patients)
had RRMS and 8.8% (5 patients) had PPMS (27). However,
Deriu et al. did not find a higher RLS prevalence in PPMS
patients (23). In our study, 15 of the 16 MS/RLS+ patients
had RRMS and only one of the 16 MS/RLS+ patient had
PRMS. We could not find any relationship between PRMS
and the presence of RLS.
Only three studies have evaluated functional system
involvement and the presence of RLS to date. Manconi
et al. showed pyramidal and sensorial functional system
scores were higher in MS/RLS+ patients than in MS/RLS–
patients (19). Aydar et al. showed that there was a significant
relationship between the pyramidal symptoms, intestinal
and bladder dysfunction, and RLS (25). In contrast, Deriu
et al. did not find any relationship between the presence
of RLS and functional system involvement (23). However,
in our study we did not find any relationship between
functional system involvement and the presence of RLS.
We found that RLS got worse during MS attacks.
Previous studies showed that MS/RLS+ patients had brain
lesions on MRI similar to those in MS/RLS– patients (19–
21,23,28). Aydar et al. reported that the number of lesions
on brain MRI was related to RLS (25). In our study, eight
MS/RLS+ and 16 MS/RLS– patients underwent brain
MRI, which was performed during MS attacks. There was
no difference in lesion localization in brain MRI between
MS/RLS+ and MS/RLS– patients, which is compatible

with previous reports. Therefore, we conclude that neither
the presence nor the worsening of RLS is related to lesion
localization in the brain.
Although the etiopathogenesis of RLS is still
unknown, impairment of dopaminergic transmission
and the iron metabolic pathway might be involved. The
primary evidence that indicates involvement of primary
dopaminergic pathology comes from the effectiveness of
dopaminergic agents in treating RLS symptoms (5). It has
been suggested that RLS might be caused by a dysfunction
of the dorsoposterior hypothalamic dopaminergic A11
cell group (2). However, in a recent study, the A11 region
showed no significant difference in brain autopsies of RLS
and age-matched control cases (33).
Although extrastriatal as well as striatal brain regions
were involved in RLS patients, reduction of the striatal
dopaminergic function in RLS has been found in some
brain PET studies (6–9). It has been suggested that
hypoactive dopaminergic neurotransmission might
contribute to the pathophysiology of RLS (9).
MS lesions in the brain may cause dysfunction in
dopaminergic pathways, although there is no association
between the brain lesion localization and the presence of
RLS. Comparing the dopamine levels in MS/RLS+ and
MS/RLS– patients may provide a clue.
There are some limitations of our study. First, family
history of RLS was not evaluated in the MS or the control
group. Although a complete blood count was performed
in all of the participants, ferritin level was not measured.
Moreover, the number of patients who underwent brain
MRI during the relapse period of MS was small.
In conclusion, in contrast to some previous reports,
there is no association of RLS with pyramidal or sensory
system involvement in MS patients. Moreover, RLS is
unrelated to EDSS score or lesions in brain MRI. In most
of the cases, RLS was manifested after the onset of MS.
Although there is no relationship between MS lesions in
brain MRI and the presence of RLS, dopaminergic activity
still might be decreased in MS patients. Dopaminergic
activity in MS/RLS+ and MS/RLS– patients should be
investigated in further studies. Moreover, the study should
be replicated with further studies and more patients.
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